Intensity of SAEs Per the Investigator's Assessment;Intensity of Unsolicited AEs Per the Investigator's Assessment Occurring on the Day of Vaccination and the Following 28 Days After Any Dose;Number of Participants Who Experienced a Medically Attended Adverse Event (AE) Occurring in the Following 6 Months After Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an AE Leading to Trial Discontinuation Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an AE Leading to Vaccine Withdrawal Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Any Dose;Number of Participants Who Experienced a Serious Adverse Event (SAE);Number of Participants Who Experienced Death Due to SAE;Occurrence of Seroconversion for SARS-CoV-2 Receptor-Binding Domain (RBD) of Spike Protein Antibodies (IgG) on Day 29 and Day 43;SARS-CoV-2 RBD of Spike Protein Antibody (IgG) Levels on Days 1, 29 and 43

Intensity of SAEs Per the Investigator's Assessment;Intensity of Unsolicited AEs Per the Investigator's Assessment Occurring on the Day of Vaccination and the Following 28 Days After Any Dose;Number of Participants Who Experienced a Medically Attended Adverse Event (AE) Occurring in the Following 6 Months After Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an AE Leading to Trial Discontinuation Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an AE Leading to Vaccine Withdrawal Occurring in the Following 1 Year After Dose 2;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Any Dose;Number of Participants Who Experienced a Serious Adverse Event (SAE);Number of Participants Who Experienced Death Due to SAE;Occurrence of Seroconversion for SARS-CoV-2 Receptor-Binding Domain (RBD) of Spike Protein Antibodies (IgG) on Day 29 and Day 43;SARS-CoV-2 RBD of Spike Protein Antibody (IgG) Levels on Days 1, 29 and 43

Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine

Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine

Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine

Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum;Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment;Intensity of Medically-attended Adverse Events per Investigator's Assessment;Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events per the Investigator's Assessment;Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies;Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Disctontinuation;Number of Participants with Death due to a Serious Adverse Event (SAE);Number of Participants with Medically-attended Adverse Events;Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Number of Participants with Unsolicited Adverse Events;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine